• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's After-Market Session

    4/1/24 4:31:02 PM ET
    $ABVC
    $ACON
    $APLM
    $BIVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • OpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million.
    • Galecto (NASDAQ:GLTO) shares increased by 9.93% to $0.82. The market value of their outstanding shares is at $22.2 million.
    • Kyverna Therapeutics (NASDAQ:KYTX) shares increased by 9.19% to $24.59. The company's market cap stands at $1.0 billion.
    • Matinas BioPharma Hldgs (AMEX:MTNB) stock increased by 8.16% to $0.4. The company's market cap stands at $86.9 million. The company's, Q4 earnings came out 3 days ago.
    • Ontrak (NASDAQ:OTRK) shares rose 7.86% to $0.48. The company's market cap stands at $13.2 million.
    • Apollomics (NASDAQ:APLM) stock rose 7.7% to $0.74. The company's market cap stands at $66.0 million. As per the press release, FY earnings came out 2 days ago.

    Losers

    • Gritstone Bio (NASDAQ:GRTS) stock decreased by 41.7% to $1.37 during Monday's after-market session. The company's market cap stands at $134.3 million.
    • Aclarion (NASDAQ:ACON) shares fell 17.08% to $0.34. The market value of their outstanding shares is at $2.4 million.
    • Qilian Intl Hldg Gr (NASDAQ:QLI) shares declined by 7.1% to $0.61. The company's market cap stands at $21.9 million.
    • BioVie (NASDAQ:BIVI) stock declined by 6.59% to $0.52. The market value of their outstanding shares is at $28.6 million.
    • ABVC BioPharma (NASDAQ:ABVC) shares fell 6.57% to $1.28. The company's market cap stands at $13.5 million.
    • Humana (NYSE:HUM) shares decreased by 6.36% to $329.11. The company's market cap stands at $39.6 billion. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ACON
    $APLM
    $BIVI

    CompanyDatePrice TargetRatingAnalyst
    Galecto Inc.
    $GLTO
    2/17/2026$45.00Buy
    UBS
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Humana Inc.
    $HUM
    1/7/2026$290.00Overweight → Equal Weight
    Wells Fargo
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Humana Inc.
    $HUM
    12/5/2025$313.00Hold → Buy
    Jefferies
    Galecto Inc.
    $GLTO
    12/1/2025$32.00Buy
    Guggenheim
    Humana Inc.
    $HUM
    10/14/2025$235.00Sell
    Goldman
    More analyst ratings

    $ABVC
    $ACON
    $APLM
    $BIVI
    SEC Filings

    View All

    SEC Form POS AM filed by ABVC BioPharma Inc.

    POS AM - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:30:55 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ABVC BioPharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ABVC BIOPHARMA, INC. (0001173313) (Filer)

    3/27/26 4:05:35 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Kyverna Therapeutics Inc.

    S-8 - Kyverna Therapeutics, Inc. (0001994702) (Filer)

    3/26/26 4:26:56 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CenterWell Shetty Sanjay K bought $150,016 worth of Humana Common (810 units at $185.21), increasing direct ownership by 7% to 11,657 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/25/26 11:48:38 AM ET
    $HUM
    Medical Specialities
    Health Care

    Director Seidenberg Beth C bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:43:43 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Westlake Biopartners Opportunity Fund I, L.P. bought $999,998 worth of shares (133,333 units at $7.50) (SEC Form 4)

    4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)

    12/22/25 11:42:37 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Humana downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Humana from Outperform to Sector Perform and set a new price target of $189.00

    2/12/26 8:16:45 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Humana from Equal-Weight to Underweight and set a new price target of $174.00

    2/2/26 6:49:06 AM ET
    $HUM
    Medical Specialities
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Chen Hung-Wen

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/19/26 2:02:48 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chen Hong-Jung

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:52:25 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Chu Yi-An

    3 - Apollomics Inc. (0001944885) (Issuer)

    3/18/26 6:46:11 PM ET
    $APLM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    Advancing first-to-market autoimmune CAR T opportunity in stiff person syndrome (SPS) with key launch preparation activities underway; BLA submission anticipated in 1H 2026 Progressing enrollment for FDA-aligned Phase 3 trial in generalized myasthenia gravis (gMG) Positive progressive multiple sclerosis data underscore valuable pipeline-in-a-product opportunity with miv-cel Cash and cash equivalents of $279 million provide expected runway into 2028, funding SPS BLA filing, commercial launch, and Phase 3 gMG trial EMERYVILLE, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a late-stage clinical biopharmaceutical company focused on developing cell th

    3/26/26 4:02:00 PM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts

    Pursuing reimbursement coverage from one or more regional insurance providers in the United States as an important step toward broader payer adoption Initial CLARITY trial readout in Q4 2026 Strong Balance Sheet with Cash Runway into 2028 BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company's

    3/19/26 6:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Financials

    Live finance-specific insights

    View All

    Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan

    BROOMFIELD, Colo., March 19, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (NASDAQ:ACON, ACONW)) ("Aclarion" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan is effective immediately and expires in one year. The Rights Plan is intended to enable all stockholders to realize the long-term value of their investment in Aclarion. The Rights Plan is also intended to reduce the likelihood that any person or group gains control of the Company without paying all stockholders an appropriate control premium. The Rights Plan will help to ensure the Board has sufficient time to

    3/19/26 9:25:40 AM ET
    $ACON
    Medical Specialities
    Health Care

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Leadership Updates

    Live Leadership Updates

    View All

    Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors

    Sravan Emany brings capital markets and commercial-stage, rare disease expertise as the Company advances towards commercialization Andrew Miller adds deep clinical development and product approval experience to support Kyverna's next phase of growth EMERYVILLE, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors. Mr. Emany will assume the role of Audit Committee Chair, following the transition of Dan Spiegelman from this position, who has stepped d

    2/24/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer

    EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is

    2/3/26 8:00:00 AM ET
    $KYTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ACON
    $APLM
    $BIVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

    SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

    11/13/24 3:06:29 PM ET
    $ACON
    Medical Specialities
    Health Care